Skip Ribbon Commands
Skip to main content
 
New Studies

Checkpoint inhibition for treating Hodgkin and Non-Hodgkin lymphoma in allo HSCT

Pneumocystis Pneumonia (PcP) after allo HSCT

Use of busulfan in the conditioning for allogeneic hematopoietic cell transplantation in adults

Retrospective study on Beta-thalassemia​

***

Checkpoint inhibition for treating Hodgkin and Non-Hodgkin lymphoma in the context of allogeneic stem cell transplantation: A survey-based registry study of the EBMT Lymphoma Working Party.

 

This study aims to investigate safety and efficacy of immune checkpoint inhibitor treatment before and after allogeneic stem cell transplantation in NHL and HL.

For more information about the Lymphoma Working Party and about this study, please click HERE

To fill in the survey please click HERE


***

A case-control study on risk factors, timing, and PCR use, for pneumocystis pneumonia (PcP) after allogeneic HSCT: A non-interventional prospective study of the EBMT Infectious Diseases Working Party.

This study aims to identify pre- and post-transplant factors associated with development of PcP after allogeneic HSCT.

For more information about the Infectious Diseases Working Party and about this study, please click HERE


***

Complications and Q​uality of Life Working Party survey of the use of busulfan in the conditioning for allogeneic hematopoietic cell transplantation in adults

This study aims to produce a statement of the current practice and recommendations for a standardized policy in the use of busulfan.

For more information about the Complications & Quality of Life Working Party and about this study, please click HERE

To fill in the survey please click HERE


***

Inborn Errors Working Party (IEWP) survey to investigate the possibility of performing a retrospective study on Beta-thalassemia

This retrospective study will give insight and will evaluate the outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT). It will certainly increase the data quality of Beta-Thalassemia patients registered in ProMISe and increases the possibility of performing new studies on Beta-Thalassemia in the future as well.

For more information about the IEWP and about this study, please click HERE​

To fill in the survey please click HERE​

Deadline: June 20 2017



 

 News

 
10/07/2017
Creation of a new EBMT Legal & Regulatory Affairs Committee (LRAC)... Read more >>
21/06/2017
June 2017 | Vol. 57 - Issue 3 ... Read more >>
17/05/2017
The EBMT implements Elsevier’s MACRO platform to upgrade patient registry.... Read more >>
05/10/2016
​EBMT TV returns to 2017 Annual Meeting... Read more >>
26/09/2016
​The EBMT has contributed to the Innovative Medicines Intiative... Read more >>
10/05/2016
​More than 60 EBMT centres have already started entering their related donor data. We want to invite... Read more >>
 

 Events

 
Bookmark and Share